NSE: INDOCO | BSE: 532612

Momentum Trap

Download real time

255.55 -6.10 (-2.33%)

28.01% Fall from 52W High

7,233 NSE+BSE Volume

NSE 03 Dec, 2025 10:52 AM (IST)

2,357.4

Market Cap

Above industry Median

Beta 1Year

Very Low volatility

Indoco Remedies Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for INDOCO, BSE:532612 Indoco Remedies Ltd.

Indoco Remedies Ltd.

01 Feb 2016

255.55

-2.33%

Indoco Remedies: Q3FY16 Result Review-Gross Margins Under Pressure, Maintain SEL... (Feb 01, 2016)

Sell: Indoco Remedies Ltd.

Recommendation Target

Karvy

Indoco Remedies Total Revenues increased by 19.4% YoY to Rs 2586 mn (in line with our estimate of Rs 2588 mn) in Q3FY16 due to higher export formulations sale. Operating margins decreased by 300bps YoY to 16.7% (lower than our estimate of 18%) due to higher staff cost, R&D and overheads.

Indoco Remedies Ltd. is trading below all available SMAs

Indoco Remedies Ltd.

10 Nov 2015

255.55

-2.33%

Indoco Remedies Ltd- Research Report

Hold: Indoco Remedies Ltd.

Angel Broking

Indoco Remedies posted lower than expected numbers for 2QFY2016. The company posted a 9.4% yoy growth in sales to Rs248cr V/s Rs272cr expected and V/s Rs226cr in 2QFY2015, on back of domestic and exports posting a growth of 1.2% and 23.6% respectively. On the operating front, the EBITDA margin came in at 15.5% V/s 20.9% expected and V/s 20.6% in 2QFY2015, on back of lower than expected sales and 28.3% yoy and 82.6% yoy rise in staff expenditure and R&D; expenditure, respectively. The R&D; expenditure during the quarter was 3.6% of sales V/s 2.2% of sales in 2QFY2015. Thus, the Adj. net profit came in at Rs22.6cr V/s Rs33.4cr expected and V/s Rs22.4cr in 2QFY2015, a yoy growth of 0.9%. The lower than expected net profit is on back of lower than expected sales and OPM. On back of valuations, we maintain our Neutral stance on the stock. Results lower than expected: The company posted lower than expected numbers for 2QFY2016. The company posted a 9.4% yoy growth in sales to Rs248cr V/s Rs272cr expected and V/s Rs226cr in 2QFY2015, on back of domestic and exports posting a growth of 1.2% and 23.6% respectively. On the operating front, the EBITDA...

Indoco Remedies Ltd. is trading below all available SMAs

Indoco Remedies Ltd.

02 Dec 2014, 12:00AM

255.55

-2.33%

Indoco Remedies Ltd (Dec 02, 2014)

Buy: Indoco Remedies Ltd.

Karvy

Indoco Remedies Ltd

Indoco Remedies Ltd. is trading below all available SMAs

Indoco Remedies Ltd.

01 Sep 2014

255.55

-2.33%

Indoco Remedies Ltd.

Buy: Indoco Remedies Ltd.

Ashika Research

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with a global presence in 80 countries including USA and UK. Indoco, a USD...

Indoco Remedies Ltd. has an average target of 325.00 from 2 brokers.

Is Indoco Remedies Ltd. worth buying?

60 Votes:

Buy 75.0%

Sell 15.0%

Hold 10.0%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Not Rated SEE REPORTS >

pdf